NCT06978725

A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Cutaneous Sarcoidosis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 28 (estimated)
• Sponsor: Priovant Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.

Conditions

• Cutaneous Sarcoidosis

Interventions

Type	Name	Description
DRUG	Oral Brepocitinib	Drug: Oral Brepocitinib
DRUG	Oral Placebo	Drug: Oral Placebo

Timeline

• Start date: 2025-04-09
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2025-05-18
• Last updated: 2025-05-18

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study